<DOC>
	<DOCNO>NCT02248116</DOCNO>
	<brief_summary>Safety tolerability . Quality life ( EQ-5D , ACQLI ) health economic impact ( health resource utilisation , live employment status ) assessment , perform center united kingdom ( UK )</brief_summary>
	<brief_title>Follow-up Trial Assess Long-term Safety Tolerability Talsaclidine Patients With Mild Moderate Dementia Alzheimer Type</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>Patient meet inclusion criterion precede talsaclidine trial Patient complete precede talsaclidine trial within last four week adequate compliance Patient able understand patient information give write informed consent accordance GCP ( good clinical practice ) local legislation . In case doubt , study independent physician ass patient . If opinion study independent physician patient unable provide write inform consent , legal guardian may provide consent behalf patient Patient relative caregiver give write informed consent provide trial related information self patient willing capable support clinical trial Patient caregiver able complete trial examination , hear , speak , read write basic way primary sensorial function intact Patient develop medical condition precede talsaclidine trial , opinion investigator may worsen participation trial Patient experience serious drug relate adverse event ( ) precede talsaclidine trial Patient drop precede talsaclidine trial Patient major protocol violator precede talsaclidine trial Untreated noncompensated hypertension ( BP systolic &gt; 180 and/or diastolic &gt; 110 mmHg ) Hypertension treat ßblockers Severe heart failure ( NYHA : III IV ) Any arrhythmias include bradycardia rate &lt; 50 bpm , arrhythmia due second third degree block low IIIV , ECG &lt; 30 ventricular extra systoles/hour , multifocal multiform repetitive form ventricular extra systole Bronchial asthma phase exacerbation inducible aspirin NSAIDSs Any patient diabetes , type I II , active treatment either insulin oral agent Renal insufficiency : calculated creatinine clearance normal range ( base gender , age weight ) Acute hepatic disorder ( liver enzymes 50 % upper normal limit ) Patient obvious symptom dehydration Neoplasm currently active likely recur ( except basal cell carcinoma , squamous cell carcinoma skin clinically significant meningioma ) Patient participate another clinical trial Pregnant lactating woman , woman childbearing potential use approved method contraception Insufficient compliance : investigator 's opinion patient caregiver unable comply protocol requirement Exclude subject less 50 kg body weight and/or calculate creatinine clearance 50 ml/min . ( It calculate central laboratory value normal range flagged central laboratory ) Patients abnormal urinalysis result infection proteinuria define : A positive urinary bacterial culture , equal great 10exp5 colony form unit ( CFU ) /ml More 10 leukocyte per high power field &gt; 2 granular cast per low power field More 10 red blood cell per high power field &gt; +1 proteinuria ( equivalent &gt; 30 mg/dl ) ratio urine protein/urine creatinine &gt; 0.3 Any patient history chronic urinary tract infection recent urinary tract infection past six month . If patient develop low urinary tract infection participation study 506.203 without sign kidney failure , allow enter study . Patients may continue trial infection confine low urinary tract without sign kidney failure , must discontinue otherwise Patients history renal stone within past six month Concomitant Therapy exclusion Benzodiazepines ( brotizolam , oxazepam , temazepam , triazolam allow ) Antidepressants include tricyclic ( trazodone allow ; clinically relevant depressed mood Selective Serotonine Reuptake Inhibitors ( SSRIs ) fluoxetine paroxetine sertraline allow ) Antipsychotics ( haloperidol risperidone allow ) Anticholinergics ( topical application promethazine allow ) Lithium Acetylcholinesterase inhibitor Monoamine oxidase inhibitor ß blocker include topical application Any concomitant therapy significant nephrotoxic potential case urinary tract infection ( e.g . aminoglycoside , antibiotic and/or radiographic contrast agent ) Hypericum perforatum ( St John 's wort ) exclude Use neuroleptic within trial : If use neuroleptic required course trial , reason document adverse event use medication limit . Use neuroleptic stop soon patient 's clinical status allow happen Patients receive cognitive training prior study entry exclude , train continue , possible , throughout trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>